BUY Retatrutide 4mg
Retatrutide (LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). The 4mg dose, administered via subcutaneous injection, is an early maintenance dose in clinical trials, reached after the 2mg starting dose to balance efficacy and tolerability. Not yet FDA-approved, it’s available only through phase 3 TRIUMPH trials (ongoing until 2026).
retatrutide dose schedule
Mechanisms of Action
Retatrutide, a triple agonist, targets GLP-1, GIP, and glucagon receptors. GLP-1 reduces appetite and slows gastric emptying, GIP enhances insulin sensitivity and fat metabolism, and glucagon increases energy expenditure by promoting fat burning. With a ~6-day half-life, it ensures sustained effects. Phase 2 trials showed 4mg achieving ~17.1% weight loss and 1.6% HbA1c reduction over 48 weeks, outperforming lower doses.
Potential Benefits
retatrutide dosing schedule
Weight Loss: Achieves ~15–17% body weight loss (30–40 lbs) at 4mg with diet and exercise.
Blood Sugar Control: Lowers HbA1c by ~1.6% in type 2 diabetes patients.
Liver Health: Reduces liver fat, aiding MASLD treatment (data extrapolated from higher doses).
Cardiometabolic Health: Improves blood pressure, triglycerides, and LDL cholesterol.
Benefits, including appetite suppression, are noticeable within 4–8 weeks and strengthen over time.
how long takes retatrutide to kick after tirzepatide
Dosage and Administration
Start at 2mg weekly for 4 weeks, then escalate to 4mg, injected into the abdomen, thigh, or upper arm, rotating sites weekly. Administer any time of day, with or without food. Escalate to 8mg or higher after 4 weeks if prescribed. Store vials refrigerated (36–46°F). If a dose is missed, inject within 4 days or skip until the next week.
Safety and Side Effects
Common side effects include nausea, vomiting, diarrhea, and constipation (15–30%), most prominent during dose escalation. Serious risks include transient heart rate increases and rare pancreatitis. Not suitable for those with thyroid cancer history or severe liver/renal issues. Monitor for severe abdominal pain or allergic reactions. Long-term data is pending.
Legal Status
Not FDA-approved; available only in clinical trials or as a research peptide from select pharmacies. Banned by WADA.
Reviews
There are no reviews yet.